LABT
Lakewood-Amedex Biotherapeutics, Inc.
There isn't enough reported data to score LABT yet.
LABT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate LABT's fundamentals.
LABT PE Valuation
LABT has no meaningful PE right now: it lost money over the past year.
LABT Forward outlook
There aren't enough analyst estimates for LABT to show an outlook.
LABT Earnings Per Share
LABT Quarterly Revenue
LABT Free Cash Flow
LABT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +103% | +720K shares |
LABT Net Leverage
LABT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LABT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 1.1 | Oversold |
| Stochastic | 5.1 | Oversold |
LABT's weekly RSI is 1 (oversold) and its Stochastic is 5 (oversold).
LABT PE vs Healthcare Sector
LABT has no meaningful PE right now: it lost money over the past year.
LABT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.65 | 45% below |
| 20 week MA | $1.61 | 78% below |
LABT is in a downtrend: it's below all two of its weekly moving averages, and 78% below its 20-week average.
LABT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $73.5 | $0.36 | -100% |
It's down 100% so far in 2026.